Abstract: A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a “maintenance” phase. The chelating agent is most preferably ethylene diamine tetraacetic acid (EDTA) and may be provided in a dosage form having an enteric coating and at least one external cathode and at least one external anode to create a galvanic current upon contact of the dosage form with the patient's intestinal contents.
Abstract: Particular nutritional supplements and protocols emphasize the use of ethylenediamine tetraacetic acid as a mouth rinse, and as an enteric-coated oral pharmaceutical, further supplemented on a daily basis with both a combination of phosphatidyl lipids and alpha lipoic acid and a nutritional supplement containing approximately equal amounts of Reishi and Shiitake mushrooms.
Type:
Application
Filed:
September 15, 2004
Publication date:
June 26, 2008
Applicant:
Med Five, Inc.
Inventors:
Ralph A. Cowden III, Alec Keith, James C. Roberts Jr., William E. Crisp, Janey A. Lau